Print This Page

VitaTech is researching how direct delivery of ATP may be able to dramatically reduce the number of people who die waiting for an organ transplant.

More than 52,000 organ transplantation surgeries take place each year, yet less than 25 percent of people on waiting lists actually receive the organs they need. Thousands of patients die each year awaiting a suitable donor.

The difficulty of matching organs to patients is compounded by the fact that organs remain viable for only a very short period of time once outside a living body. An organ's short-term viability is directly related to ATP depletion.

Preserving organs twice as long

VitaTech has shown in numerous rodent studies that its technology can double the preservation period, compared to organs preserved without ATP. It also results in less liver dysfunction, demonstrated by decreased liver-specific enzyme levels compared to the control organs. The longer the viability of harvested organs, the greater the likelihood of matching them to patients who need them.